anti-CD19-TCRz-CD137 CAR-T (f4b2fc)

anti-CD19-TCRz-CD137 CAR-T is an autologous, second-generation chimeric antigen receptor (CAR) T-cell therapy developed by The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine. The CAR construct is composed of an anti-CD19 single-chain variable fragment (scFv) for tumor targeting, a CD137 (4-1BB) costimulatory domain to promote T-cell persistence and metabolic fitness, and a CD3-zeta (TCRz) signaling domain for T-cell activation. It is primarily investigated for the treatment of B-cell malignancies, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and various subtypes of non-Hodgkin lymphoma such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). In clinical research (notably the MatchCART study), this agent is often compared directly with CD28-costimulated CAR-T cells to evaluate differences in engraftment and long-term efficacy.

Other names

CD19-4-1BB-CD3z CAR-TCD-19-4-1BB-CD3z CAR-TCD 19-4-1BB-CD3z CAR-TCD19-CD137-CD3zeta CAR-TCD-19-CD137-CD3zeta CAR-TCD 19-CD137-CD3zeta CAR-Tanti-CD19-TCRz-CD137 CAR-T-The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine-acute lymphoblastic leukemia-chronic lymphocytic leukemia-diffuse large B-cell lymphoma-follicular lymphoma-mantle cell lymphomaanti-CD-19-TCRz-CD137 CAR-T-The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine-acute lymphoblastic leukemia-chronic lymphocytic leukemia-diffuse large B-cell lymphoma-follicular lymphoma-mantle cell lymphomaanti-CD 19-TCRz-CD137 CAR-T-The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine-acute lymphoblastic leukemia-chronic lymphocytic leukemia-diffuse large B-cell lymphoma-follicular lymphoma-mantle cell lymphoma